Premium
Ultrasound and radionuclide scans—poor indicators of liver damage in patients treated with methotrexate
Author(s) -
MITCHELL DEBORAH,
JOHNSON R.J.,
TESTA H.J.,
HABOUBI N.Y.,
CHALMERS R.J.G.
Publication year - 1987
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/j.1365-2230.1987.tb01911.x
Subject(s) - medicine , methotrexate , cirrhosis , ultrasound , liver biopsy , biopsy , radiology , nuclear medicine , gastroenterology
Summary Ultrasound and radionuclide scans of the liver were compared with biopsy histology as a means of assessing hepatotoxicity in 49 psoriatic patients receiving methotrexate, Ultrasound failed to identify any of the 12 patients with hepatic fibrosis or cirrhosis, Radionuclide scans in one out of three patients with cirrhosis, and five out of nine patients with libmsis, were reported as normal. Neither method can reliably replace liver biopsy in detecting significant methotrexate‐induced hepatotoxicity in psoriatic patients.